Challenges and Opportunities in the Development of Organometallic Anticancer Drugs
Top Cited Papers
- 16 July 2012
- journal article
- review article
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 31 (16), 5677-5685
- https://doi.org/10.1021/om300373t
Abstract
No abstract availableKeywords
This publication has 139 references indexed in Scilit:
- Physicochemical Studies and Anticancer Potency of Ruthenium η6-p-Cymene Complexes Containing Antibacterial QuinolonesOrganometallics, 2011
- Novel benzyl-substituted N-heterocyclic carbene–silver acetate complexes: synthesis, cytotoxicity and antibacterial studiesMetallomics, 2011
- Organometallic Anticancer CompoundsJournal of Medicinal Chemistry, 2010
- Sequence‐Selective Organoiridium DNA Bis‐Intercalators with Flexible Dithiaalkane Linker ChainsEuropean Journal of Inorganic Chemistry, 2010
- Controlling platinum, ruthenium, and osmium reactivity for anticancer drug designAdvances in Inorganic Chemistry, 2009
- The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF KinaseBiochemistry, 2009
- Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer ActivityJournal of Medicinal Chemistry, 2009
- Anticancer Activity of Ag(I) N-Heterocyclic Carbene Complexes Derived from 4,5-Dichloro-1H-ImidazoleMetal-Based Drugs, 2008
- Similar Biological Activities of Two Isostructural Ruthenium and Osmium ComplexesChemistry – A European Journal, 2008
- Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinomaEuropean Journal Of Cancer, 2004